Compare MEHA & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEHA | SHPH |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.1M |
| IPO Year | N/A | 2022 |
| Metric | MEHA | SHPH |
|---|---|---|
| Price | $0.17 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.2M | 65.4K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.12 |
| 52 Week High | $0.74 | $5.59 |
| Indicator | MEHA | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 42.52 |
| Support Level | N/A | $0.80 |
| Resistance Level | $0.29 | $2.00 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 5.71 | 61.90 |
Functional Brands Inc operates in the nutraceutical supplement industry. It is a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, brain and memory, sleep, prenatal and urinary. It is focus on end-consumers through different channels that include pharmacies, wholesalers, international distributors and direct-to-consumers sales. The Company has two reportable segments: 1) Kirkman, which sells a range of nutraceuticals, supplements and related products direct to consumers; 2) HT Naturals, which sells a range of hemp products; and 3) Corporate, which generates no revenue. Key revenue is generated from Kirkman.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.